Carcinogenicity Risk Assessment Report

Our CRA reports follow the Weight of Evidence (WoE) approach presented in the ICH S1B(R1) addendum that was approved by the FDA and EMA. The reports present a comprehensive assessment of the data relevant to carcinogenic potential available from public sources and from relevant drug development studies.